On this page
Gentamicin Sulfate
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Gentamicin Sulfate | 3 mg/mL | 1870650 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Aminoglycoside Antibacterial [EPC] | EPC | All 66 members |
| Aminoglycosides [CS] | CS | All 66 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 062196-001 | GENTAMICIN SULFATE | SOLUTION/DROPS | GENTAMICIN SULFATE | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 15 | Manufacturing (CMC) | Approved | December 23, 2002 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | November 17, 2000 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | September 12, 2000 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | April 28, 2000 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | April 7, 2000 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | May 7, 1999 | — |
| Supplement | 5 | Labeling | Approved | September 18, 1998 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | April 3, 1998 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | July 29, 1997 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | July 29, 1997 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | June 9, 1997 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | December 9, 1996 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | July 12, 1996 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | December 28, 1995 | — |
| Original application | 1 | Approved | July 2, 1980 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250501). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Gentamicin Sulfate Ophthalmic Solution is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION : Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops once every hour.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Gentamicin Sulfate Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of the components.
Warnings
openFDA Drug LabelingWARNINGS: NOT FOR INJECTION INTO THE EYE. Gentamicin Sulfate Ophthalmic Solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations. The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura, and hallucinations. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Gentamicin Sulfate is a water-soluble antibiotic of the aminoglycoside group. Gentamicin Sulfate Ophthalmic Solution is a sterile, aqueous solution buffered to approximately pH 7 for ophthalmic use. Gentamicin is obtained from cultures of Micromonospora purpurea . It is a mixture of the sulfate salts of gentamicin C 1 , C 2 , and C 1A . All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as white powder and is soluble in water and insoluble in alcohol. The structure is as follows: Established name: Gentamicin Sulfate Chemical name: 0-3-Deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-0-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-D-streptamine. Ingredients: Each mL contains: Active: Gentamicin Sulfate USP (equivalent to 3 mg gentamicin). Preservative: Benzalkonium Chloride 0.1 mg (0.01%). Inactives: Dibasic Sodium Phosphate Anhydrous, Sodium Chloride, Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH), Tyloxapol and Purified Water. chemicalstructure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: Gentamicin Sulfate Ophthalmic Solution: 5 mL in plastic DROP-TAINER * dispenser. NDC 71205-333-05 STORAGE: Protect from light and store away from heat. Store at controlled room temperature 15°-25°C (59°-77°F). To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. *DROP-TAINER is a registered trademark of Alcon Research, Ltd. Rx Only
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: GENTAMICIN SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 76420-137-05 | 76420-137 | Asclemed USA, Inc. | 5 mL in 1 BOTTLE, PLASTIC (76420-137-05) | March 4, 2022 |
| 68071-4775-5 | 68071-4775 | NuCare Pharmaceuticals,Inc. | 5 mL in 1 BOTTLE (68071-4775-5) | February 20, 2019 |
| 71205-333-05 | 71205-333 | Proficient Rx LP | 5 mL in 1 BOTTLE, PLASTIC (71205-333-05) | September 1, 2019 |
| 61314-633-05 | 61314-633 | Sandoz Inc | 1 BOTTLE, DROPPER in 1 CARTON (61314-633-05) / 5 mL in 1 BOTTLE, DROPPER | April 5, 1996 |
| 76420-137 | 76420-137 | Asclemed USA, Inc. | — | April 5, 1996 |
| 68071-4775 | 68071-4775 | NuCare Pharmaceuticals,Inc. | — | April 5, 1996 |
| 71205-333 | 71205-333 | Proficient Rx LP | — | April 5, 1996 |
| 61314-633 | 61314-633 | Sandoz Inc | — | April 5, 1996 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.